(Q37778398)

23 August 2017

1 reference

title

Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review (English)

1 reference

23 August 2017

0 references

2

Hans-Jürgen Möller

1 reference

23 August 2017

Fernando Cañas

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

full work available at URL

23 August 2017

http://www.informapharmascience.com/doi/abs/10.1517/14740338.2010.506712

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20690885

http://www.tandfonline.com/doi/pdf/10.1517/14740338.2010.506712

17 June 2024

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Expert Opinion on Drug Safety

17 June 2024

published in

1 reference

23 August 2017

volume

9

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

683-697

1 reference

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Partial compliance in schizophrenia and the impact on patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Partial compliance with antipsychotic medication is common in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Risk profiles for non-adherence to antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Tactics and technologies to manage nonadherence in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Compliance with depot antipsychotic medication by patients attending outpatient clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Factors affecting compliance with depot injection treatment in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-acting risperidone: focus on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-acting risperidone in stable patients with schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-acting risperidone improves negative symptoms in stable psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Direct transition to long-acting risperidone--analysis of long-term efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.506712

Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.

17 June 2024

10

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

17 June 2024

12

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.

17 June 2024

16

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression

17 June 2024

18

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Attitudes of psychiatrists toward antipsychotic depot medication

17 June 2024

25

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

The attitude of patients towards antipsychotic depot treatment

17 June 2024

26

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Depot and oral antipsychotics: patient preferences and attitudes are not the same thing

17 June 2024

27

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study

17 June 2024

43

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Long-term treatment with long-acting risperidone in Korean patients with schizophrenia

17 June 2024

44

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

17 June 2024

47

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.

17 June 2024

51

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

Risperidone Long-Acting Injection

17 June 2024

54

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

17 June 2024

57

1 reference

https://api.crossref.org/works/10.1517/14740338.2010.506712

17 June 2024

Identifiers

1 reference

23 August 2017

1 reference